The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition.
The post BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes appeared first on MedCity News.
